Abstract: Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.

Abstract: The disclosure discloses a fatty acid synthase inhibitor and application thereof and belongs to the technical field of medical biology. The fatty acid synthase inhibitor of the disclosure can significantly inhibit the activity of fatty acid synthase without affecting normal expression, and adjust the ratio of fatty acids in cells. The fatty acid synthase inhibitor of the disclosure has a good tumor proliferation inhibitory effect, can arrest the growth cycle of tumor cells in the interphase, prevent tumor cell division, inhibit tumor cell proliferation, promote tumor cell apoptosis and exert a tumor treatment effect, can be used to treat tumors and metabolism related diseases, and has an important clinical application prospect.

Abstract: Provided are a boron-silicon heterocyclic compound having a structure represented by formula 1, a display device and a display apparatus. In formula 1, L1 and L2 are each a single bond, C6-C30 arylene, C6-C30 fused arylene, C4-C30 heteroarylene, or C4-C30 fused heteroarylene; D1 and D2 are each a substituted or unsubstituted C6-C60 aryl, a substituted or unsubstituted C4-C60 heteroaryl, a substituted or unsubstituted C10-C60 fused aryl, a substituted or unsubstituted C8-C30 fused heteroaryl, or a substituted or unsubstituted diphenylamino. The compound has a strong inductive effect and can reduce the driving voltage of the device. The silacyclopentadiene having a silicon atom as spiro-atom can effectively improve the solubility of the material, which is beneficial to the cleaning of the vapor deposition mask. In addition, the compound has a higher triplet energy level to effectively transfer energy to the luminous body, and improves the efficiency of the device.

Abstract: Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.

Abstract: The present disclosure provides a compound having a formula (I): wherein Cy represents substituted or unsubstituted C5-C40 aryl; X represents oxygen atom or sulfur atom; L1 is selected from substituted or unsubstituted C5-C40 aryl, or substituted or unsubstituted C3-C40 heteroaryl; A includes a structure represented by formula (II): wherein each of L2 and L3 is independently selected from substituted or unsubstituted C5-C40 aryl, or substituted or unsubstituted C3-C40 heteroaryl; each of Ar1, Ar2, and Ar3 is independently selected from substituted or unsubstituted C5-C40 aryl, substituted or unsubstituted C3-C40 heteroaryl, or substituted or unsubstituted arylamine containing one or two nitrogen atoms; each of m, q, and r is independently selected from 0 or 1; and * indicates a connection position.

Abstract: Disclosed are a crystal form of a compound (I) and a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn’s disease. The crystal form of compound I has one or more improved properties compared with the prior art and is of great value to the future optimization and development of the drug.

Abstract: A crystal form of a compound I and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in the preparation of a TYK2 inhibitor drug and a drug for treating psoriasis, systemic lupus erythematosus, and Crohn's disease. The crystallization of the compound I has one or more improved properties compared to the existing technology, and has an important value to the future optimization and development of the drug.

Abstract: Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.

Abstract: The present disclosure provides a method for preparing patterned graphene, and the method includes using a silicon carbide base as a solid-state carbon source, decomposing the silicon carbide under the action of high temperature and catalyst, to directly grow graphene on an insulating substrate. Through a first patterned trench and a second patterned trench in an accommodating passage, the pattern of the formed graphene can be directly controlled. Therefore, the present disclosure can accurately locate the position of the patterned graphene on the insulating substrate, it does not require transferring the graphene one more time, thereby avoiding contaminating the graphene and damaging its structure, and there is no need for photo-lithography, ion etching and other processes to treat the graphene in order to obtain patterned graphene, which further avoids damages to the graphene.

Abstract: A compound according to Formula (1), in which D is an electron donor containing a nitrogen atom and is bonded to a benzene ring through the nitrogen atom; A is an electron acceptor containing a boron atom and is bonded to a benzene ring through the boron atom; m and n are each an integer selected from 1, 2 or 3; and R11, R12, R13, R14 are each independently selected from the group consisting of a hydrogen atom, alkyl, alkoxy, cyano, trifluoromethyl, an electron acceptor A?, and a nitrogen-containing electron donor D. In the compound, biphenyl acts as a linking unit between the electron donor D and the electron acceptor A, such that units D and A are located at different positions of the molecule, realizing effective separation between HOMO and LUMO. In addition, the light absorption and vibration strength of the molecule are enhanced.

Abstract: The present disclosure provides a compound used as the CPL material. The compound has a structure as shown in chemical formula I, in which L1 is selected from the group consisting of a substituted or unsubstituted C6-C30 arylene, C3-C30 heteroarylene, a substituted or unsubstituted C10-C60 fused arylene, and a substituted or unsubstituted C10-C60 fused heteroarylene; Ar1 is selected from the group consisting of a substituted or unsubstituted C6-C30 arylene, C3-C30 heteroarylene, a substituted or unsubstituted C10-C60 fused arylene, and a substituted or unsubstituted C10-C60 fused heteroarylene; n is 1 or 2, and when n is 2, the two Ar1 are identical or different; R1, R2, R3 and R4 are each independently selected from the group consisting of hydrogen, and a substituted or unsubstituted aryl or fused aryl, R1 and R2 are optionally bonded to form a ring, and R3 and R4 are optionally bonded to form a ring.

Abstract: The present disclosure provides a compound having a formula (I): wherein Cy represents substituted or unsubstituted C5-C40 aryl; X represents oxygen atom or sulfur atom; L1 is selected from substituted or unsubstituted C5-C40 aryl, or substituted or unsubstituted C3-C40 heteroaryl; A includes a structure represented by formula (II): wherein each of L2 and L3 is independently selected from substituted or unsubstituted C5-C40 aryl, or substituted or unsubstituted C3-C40 heteroaryl; each of Ar1, Ar2, and Ar3 is independently selected from substituted or unsubstituted C5-C40 aryl, substituted or unsubstituted C3-C40 heteroaryl, or substituted or unsubstituted arylamine containing one or two nitrogen atoms; each of m, q, and r is independently selected from 0 or 1; and * indicates a connection position.

Abstract: Provided are a compound represented by formula 1, a display panel and display apparatus. In formula 1, L1-L5 are each a linking group independently selected from the group consisting of a single bond, C1-C10 alkylene, C6-C30 arylene, C6-C30 fused arylene, C4-C30 heteroarylene, and C4-C30 fused heteroarylene; R1-R5 are each independently selected from the group consisting of hydrogen, aryl and heteroaryl; and a, b, c, d, and e are each independently 0, 1, 2, or 3. The compound has a spirane structure containing a boron heterocyclic ring and can be used as a light-emitting host material of OLEDs. By introducing the bipolar host material into the OLED, charge transfer balance is beneficially balanced in the light-emitting layer, which broadens exciton recombination region, simplifies device structure, and improves device efficiency.

Abstract: Provided are a boron-silicon heterocyclic compound having a structure represented by formula 1, a display device and a display apparatus. In formula 1, L1 and L2 are each a single bond, C6-C30 arylene, C6-C30 fused arylene, C4-C30 heteroarylene, or C4-C30 fused heteroarylene; D1 and D2 are each a substituted or unsubstituted C6-C60 aryl, a substituted or unsubstituted C4-C60 heteroaryl, a substituted or unsubstituted C10-C60 fused aryl, a substituted or unsubstituted C8-C30 fused heteroaryl, or a substituted or unsubstituted diphenylamino. The compound has a strong inductive effect and can reduce the driving voltage of the device. The silacyclopentadiene having a silicon atom as spiro-atom can effectively improve the solubility of the material, which is beneficial to the cleaning of the vapor deposition mask. In addition, the compound has a higher triplet energy level to effectively transfer energy to the luminous body, and improves the efficiency of the device.

Abstract: A display panel includes a light-emitting element and a capping layer disposed at a light exit side of the light-emitting element. The light-emitting element includes a first light-emitting element, a second light-emitting element and a third light-emitting element emitting a first color light, a second color light and a third color light, respectively. The capping layer includes a first capping layer and a second capping layer stacked together. The second capping layer includes a first sub-capping layer, a second sub-capping layer and a third sub-capping layer correspondingly disposed at light exit sides of the first light-emitting element, the second light-emitting element and the third light-emitting element, respectively. At least one of the first sub-capping layer, the second sub-capping layer, or the third sub-capping layers is configured to have a larger refractive index of light emitted by the corresponding light-emitting element than light emitted by other light-emitting elements.

Abstract: A compound according to Formula (1), in which D is an electron donor containing a nitrogen atom and is bonded to a benzene ring through the nitrogen atom; A is an electron acceptor containing a boron atom and is bonded to a benzene ring through the boron atom; m and n are each an integer selected from 1, 2 or 3; and R11, R12, R13, R14 are each independently selected from the group consisting of a hydrogen atom, alkyl, alkoxy, cyano, trifluoromethyl, an electron acceptor A?, and a nitrogen-containing electron donor D. In the compound, biphenyl acts as a linking unit between the electron donor D and the electron acceptor A, such that units D and A are located at different positions of the molecule, realizing effective separation between HOMO and LUMO. In addition, the light absorption and vibration strength of the molecule are enhanced.

Abstract: A display panel comprises a light-emitting element and a capping layer disposed at a light exit side of the light-emitting element. The light-emitting element includes a first light-emitting element, a second light-emitting element and a third light-emitting element emitting a first color light, a second color light and a third color light, respectively. The capping layer includes a first capping layer and a second capping layer stacked together. The second capping layer includes a first sub-capping layer, a second sub-capping layer and a third sub-capping layer correspondingly disposed at light exit sides of the first light-emitting element, the second light-emitting element and the third light-emitting element, respectively. At least one of the first sub-capping layer, the second sub-capping layer, or the third sub-capping layers is configured to have a larger refractive index of light emitted by the corresponding light-emitting element than light emitted by other light-emitting elements.

Abstract: The present disclosure provides a compound used as the CPL material. The compound has a structure as shown in chemical formula I, in which L1 is selected from the group consisting of a substituted or unsubstituted C6-C30 arylene, C3-C30 heteroarylene, a substituted or unsubstituted C10-C60 fused arylene, and a substituted or unsubstituted C10-C60 fused heteroarylene; Ar1 is selected from the group consisting of a substituted or unsubstituted C6-C30 arylene, C3-C30 heteroarylene, a substituted or unsubstituted C10-C60 fused arylene, and a substituted or unsubstituted C10-C60 fused heteroarylene; n is 1 or 2, and when n is 2, the two Ar1 are identical or different; R1, R2, R3 and R4 are each independently selected from the group consisting of hydrogen, and a substituted or unsubstituted aryl or fused aryl, R1 and R2 are optionally bonded to form a ring, and R3 and R4 are optionally bonded to form a ring.

Abstract: Provided is a host material compound having a structure represented by Formula (I): in which m and n, respectively representing the number of electron donors D and the number of electron acceptors A, are each 1, 2 or 3; p and q, respectively representing the number of the group L1 and the number of the group L2, are each 0, 1, or 2. D, L1 and L2 are each alkyl, cycloalkyl, heterocyclic group, aryl, heteroaryl, fused aryl, or fused heteroaryl; and A is selected from nitrogen-containing heterocyclic substituents, cyano-containing substituents, triaryl-boron-derived substituents, and phosphorus oxygen double bond-containing substituents. The compound has a D-(?)-?-(?)-A structure with bipolarity, and the ? bond can interrupt an intramolecular charge transfer between D and A, so that the excited state is limited to a local excited state in moiety of D or A, and the compound has a small excited-state dipole moment.